Gesser Borbala, Rasmussen Mads K, Iversen Lars
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Psoriasis (Auckl). 2020 Mar 31;10:1-11. doi: 10.2147/PTT.S234151. eCollection 2020.
Dimethyl fumarate (DMF) has an inhibitory effect on the production of pro-inflammatory proteins from different cells which participate in the immune reaction in psoriatic skin. Most recently it was shown that DMF is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases (RSK1, 2), determined by X-ray crystallography. DMF binds to a specific cysteine residue in RSK2 and in the closely related mitogen and stress-activated kinases 1 (MSK1) which inhibits further downstream activation.
The aim of this study was to review the literature on the effects of DMF on activation of MSK1, RSK1, 2 kinases, and downstream transcription factors NF-κB/p65 and IκBα in cells contributing to the pathogenesis of psoriasis. We also hypothesized and studied if treatment with DMF would inhibit the activation of MSK1, RSK1, 2 kinases in peripheral blood mononuclear cells (PBMCs) in psoriatic patients.
PBMCs were purified from patients with severe psoriasis before and after 90 days of treatment with DMF. Cells were stimulated with anisomycin, IL-1β or EGF for 10 and 20 minutes. The levels of phosphorylation of MSK1, RSK1, 2 or NF-κB/p65, IκBα were analyzed by Western blotting.
Our case study showed that treatment with DMF inhibited the activation of MSK1 and RSK1, 2 kinases in PBMCs in patients. This supports that DMF is the active metabolite in vivo in psoriatic patients during DMF treatment.
Pro-inflammatory proteins are induced through activation of MSK1 and NF-κB/p65 at (S276). The extracellular signal-regulated kinases (ERK1/2) control cell survival by activating both MSK1 and RSK1, 2 kinases. P-RSK1, 2 activates P-κBα and NF-κB/p65 at (S536). The phosphorylation of NF-κB/p65 at (S276) and (S536) controls different T cell and dendritic cell functions. DMF´s inhibitory effect on MSK1 and RSK1, 2 kinase activations reduces multiple immune reactions in psoriatic patients.
富马酸二甲酯(DMF)对参与银屑病皮肤免疫反应的不同细胞中促炎蛋白的产生具有抑制作用。最近通过X射线晶体学研究表明,DMF是p90核糖体S6激酶(RSK1、2)的变构共价抑制剂。DMF与RSK2以及密切相关的丝裂原和应激激活激酶1(MSK1)中的特定半胱氨酸残基结合,从而抑制进一步的下游激活。
本研究旨在综述有关DMF对参与银屑病发病机制的细胞中MSK1、RSK1、2激酶以及下游转录因子NF-κB/p65和IκBα激活作用的文献。我们还进行了假设并研究DMF治疗是否会抑制银屑病患者外周血单核细胞(PBMC)中MSK1、RSK1、2激酶的激活。
从重度银屑病患者中纯化PBMC,在DMF治疗90天前后进行检测。用茴香霉素、IL-1β或EGF刺激细胞10分钟和20分钟。通过蛋白质免疫印迹法分析MSK1、RSK1、2或NF-κB/p65、IκBα的磷酸化水平。
我们的病例研究表明,DMF治疗可抑制患者PBMC中MSK1和RSK1、2激酶的激活。这支持了DMF是银屑病患者在DMF治疗期间体内的活性代谢产物。
促炎蛋白通过MSK1和NF-κB/p65在(S276)位点的激活而诱导产生。细胞外信号调节激酶(ERK1/2)通过激活MSK1和RSK1、2激酶来控制细胞存活。P-RSK1、2在(S536)位点激活P-κBα和NF-κB/p65。NF-κB/p65在(S276)和(S536)位点的磷酸化控制不同的T细胞和树突状细胞功能。DMF对MSK1和RSK1、2激酶激活的抑制作用减少了银屑病患者的多种免疫反应。